New Dual Agonist Survodutide Cuts Weight 13% But Side Effects Drive One in Five to Quit

Survodutide, an investigational drug that activates both glucagon and GLP-1 receptors simultaneously, has shown meaningful results for weight loss and liver health in phase III clinical trials — but its tolerability profile raises questions about how broadly it can be used in practice.

In the SYNCHRONIZE-1 trial, 725 adults with obesity (but without diabetes) were randomized to once-weekly survodutide at 3.6 mg or 6.0 mg, or placebo, over 76 weeks. Participants also received lifestyle counseling. Mean body weight loss reached 12.2% and 13% in the two survodutide groups respectively, versus 5.4% for placebo. Critically, investigators confirmed the weight lost was predominantly fat tissue — not lean mass — a key concern in obesity pharmacotherapy.

A parallel MASLD trial showed survodutide also reduced liver fat, addressing a major unmet need in metabolic liver disease, which affects hundreds of millions globally and has few approved treatments. The drug did not increase glycated hemoglobin in non-diabetic participants, and a prior phase 2 study found it actually lowered HbA1c in people with type 2 diabetes.

The major concern is tolerability. Gastrointestinal adverse events affected 81–90% of survodutide-treated patients, compared to 48% on placebo. These events caused 17.8–20.2% of treated patients to discontinue — versus just 2.9% on placebo. Researchers noted the trial's rigid forced-titration protocol likely worsened dropout rates, and suggested more flexible real-world dosing could reduce this problem.

For health-conscious readers, survodutide represents the next wave of obesity pharmacology — combining GLP-1 with glucagon receptor activation to potentially surpass existing agents like semaglutide. However, its side effect burden currently limits its profile. No deaths were reported. The drug remains investigational and is not yet approved.